IP Library › Assignment 047445/0286
Patent Assignment
Reel/Frame 047445/0286

Release of Security Interest

Recorded: 2018-11-07 Pages: 28
Assignor
OXFORD FINANCE LLC
Executed: 2018-11-05
Assignee
REGULUS THERAPEUTICS INC.
10614 SCIENCE CENTER DR., SAN DIEGO, CALIFORNIA, 92121
Covered Properties (16)
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 8,969,317 →
Application: 13/869,177 →
Publication: US 2013/0289093
Methods for Treatment of Alport Syndrome
Patent: 9,012,423 →
Application: 14/048,827 →
Publication: US 2014/0100263
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 9,181,547 →
Application: 14/111,976 →
Publication: US 2014/0107183
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 8,912,161 →
Application: 14/444,406 →
Publication: US 2014/0329887
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 9,267,137 →
Application: 14/597,676 →
Publication: US 2015/0218558
Methods for Treatment of Alport Syndrome
Patent: 9,359,609 →
Application: 14/677,387 →
Publication: US 2015/0299704
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 9,790,496 →
Application: 14/883,055 →
Publication: US 2016/0138016
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 9,688,985 →
Application: 14/995,432 →
Publication: US 2016/0244753
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 9,994,846 →
Application: 15/029,535 →
Publication: US 2016/0333341
Methods for Treatment of Alport Syndrome
Patent: 9,688,986 →
Application: 15/151,290 →
Publication: US 2016/0319283
Microrna Compounds and Methods for Modulating Mir-21 Activity
Patent: 9,970,009 →
Application: 15/441,590 →
Publication: US 2017/0240891
Methods for Treatment of Alport Syndrome
Patent: 9,970,011 →
Application: 15/606,554 →
Publication: US 2017/0369879
Microrna Compounds and Methods for Modulating Mir-21 Activity
Application: 15/704,749 →
Publication: US 2018/0155719
Methods for Treatment of Alport Syndrome
Application: 15/948,450 →
Publication: US 2018/0298385
MicroRNA Compounds and Methods for Modulating MIR-21 Activity
Application: 15/954,159 →
Publication: US 2018/0305691
MicroRNA Compounds and Methods for Modulating MIR-21 Activity
Application: 15/976,060 →
Publication: US 2018/0355355
Related Assignments (7)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 16, 2013
From: BHAT, BALKRISHEN; MARCUSSON, ERIC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 030430/0138 →
Assignment of Assignor's Interest Dec 20, 2013
From: BHAT, BALKRISHEN
To: REGULUS THERAPEUTICS INC.
Reel/Frame 031825/0801 →
Assignment of Assignor's Interest Jan 2, 2014
From: DUFFIELD, JEREMY; BHAT, BALKRISHEN; MACKENNA, DEIDRE
To: REGULUS THERAPEUTICS INC.
Reel/Frame 031872/0727 →
Assignment of Assignor's Interest Jul 29, 2014
From: BHAT, BALKRISHEN
To: REGULUS THERAPEUTICS INC.
Reel/Frame 033409/0114 →
Security Interest Aug 8, 2018
From: REGULUS THERAPEUTICS INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
Reel/Frame 046748/0561 →
Assignment of Assignor's Interest Jun 3, 2019
From: REGULUS THERAPEUTICS INC.
To: SANOFI
Reel/Frame 049344/0688 →
Release of Security Interest May 14, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
To: REGULUS THERAPEUTICS INC.
Reel/Frame 067402/0782 →